Epigenomics in aortic dissection: From mechanism to therapeutics

Life Sci. 2023 Dec 15:335:122249. doi: 10.1016/j.lfs.2023.122249. Epub 2023 Nov 6.


Aortic dissection (AD) has an unfavorable prognosis. It requires early diagnosis, appropriate treatment strategies, and suspicion to recognize symptoms; thus, it is commonly described as an acute aortic emergency. The clinical manifestations of painless AD are complex and variable. However, there is no effective treatment to prevent the progression of AD. Therefore, study of the molecular targets and mechanisms of AD to enable prevention or early intervention is particularly important. Although multiple gene mutations have been proposed as linked to AD development, evidence that multiple epigenetic elements are strongly associated is steadily increasing. These epigenetic processes include DNA methylation, N6-methyladenosine, histone modification, non-histone posttranslational modification, and non-coding RNAs (ncRNAs). Among these processes, resveratrol targeting Sirtuin 1 (SIRT1), 5-azacytidine (5azaC) targeting DNA methyltransferase (DNMT), and vitamin C targeting ten-eleven translocation 2 (Tet2) showed unique advantages in improving AD and vascular dysfunction. Finally, we explored potential epigenetic drugs and diagnostic methods for AD, which might provide options for the future.

Keywords: Aortic dissection; DNA methylation; Epigenetic therapy; Histone modification; Non-coding RNAs.

Publication types

  • Review

MeSH terms

  • Aorta
  • Aortic Dissection* / drug therapy
  • Aortic Dissection* / genetics
  • DNA Methylation
  • Epigenesis, Genetic
  • Epigenomics*
  • Humans